Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
The medication works by improving insulin sensitivity, enhancing feelings of fullness, and possibly boosting energy expenditure, all of which are essential for lasting weight loss
Diabetes 68 , 17091716 (2019)
albicans adhesion to the epithelium by preferentially binding to the components of C
10.1016/j.freeradbiomed.2009.08.021 30
In addition, there was a significant nonlinear relationship between dose (2 g/day) and changes in insulin, as well as a significant linear relationship between the duration (weeks) (coefficients = 16.45, p = 0.004) of intervention and changes in HbA1C